Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kedrion IVIg 10% in Pediatric Patients with Primary Immunodeficiency Disease
NCT04944979Phase 3Active, not recruiting
- Sponsor
- Kedrion Biopharma
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Biologic
- Countries
- 6
01
Overview
A Phase 3 trial of immune globulin intravenous (human) in primary immunodeficiency disease (PID), sponsored by Kedrion Biopharma. Started Mar 2021; status: active, not recruiting.
02
Drugs
immune globulin intravenous (human)
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT04944979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944979.